Barclays PLC Reiterates “Hold” Rating for Mazor Robotics Ltd. (MZOR)

Mazor Robotics Ltd. (NASDAQ:MZOR)‘s stock had its “hold” rating reaffirmed by equities research analysts at Barclays PLC in a report issued on Wednesday. They currently have a $34.00 price objective on the medical instruments supplier’s stock. Barclays PLC’s target price would indicate a potential downside of 34.99% from the company’s previous close.

Several other equities research analysts have also commented on MZOR. Needham & Company LLC restated a “hold” rating on shares of Mazor Robotics in a research report on Thursday, July 6th. Zacks Investment Research lowered Mazor Robotics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services set a $54.00 price objective on Mazor Robotics and gave the stock a “buy” rating in a research report on Wednesday, August 30th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. Mazor Robotics currently has a consensus rating of “Hold” and an average price target of $37.67.

Shares of Mazor Robotics (NASDAQ:MZOR) opened at 52.30 on Wednesday. The firm’s 50-day moving average is $47.38 and its 200-day moving average is $39.22. Mazor Robotics has a 1-year low of $20.19 and a 1-year high of $55.66. The company’s market cap is $1.26 billion.

Mazor Robotics (NASDAQ:MZOR) last released its quarterly earnings data on Tuesday, August 1st. The medical instruments supplier reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.09. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The business had revenue of $15.46 million for the quarter, compared to analyst estimates of $15.38 million. During the same quarter in the prior year, the firm posted ($0.09) EPS. The business’s quarterly revenue was up 86.7% compared to the same quarter last year. On average, equities analysts forecast that Mazor Robotics will post ($0.77) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2956380/barclays-plc-reiterates-hold-rating-for-mazor-robotics-ltd-mzor.html.

Several large investors have recently made changes to their positions in MZOR. Quantbot Technologies LP purchased a new position in shares of Mazor Robotics during the 2nd quarter valued at approximately $135,000. JPMorgan Chase & Co. lifted its position in shares of Mazor Robotics by 398.5% during the 1st quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock valued at $208,000 after buying an additional 5,579 shares in the last quarter. BB&T Securities LLC purchased a new position in shares of Mazor Robotics during the 2nd quarter valued at approximately $248,000. Dimensional Fund Advisors LP lifted its position in shares of Mazor Robotics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock valued at $296,000 after buying an additional 641 shares in the last quarter. Finally, ProVise Management Group LLC purchased a new position in shares of Mazor Robotics during the 2nd quarter valued at approximately $422,000. Hedge funds and other institutional investors own 25.92% of the company’s stock.

About Mazor Robotics

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Analyst Recommendations for Mazor Robotics (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.